[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, Bensussan A, Bizzini B, Gallo RC, Zagury D, Uzan G: VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A; 2007 Feb 20;104(8):2837-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.
  • Tumor growth depends on blood supply, requiring the development of new vessels, and vascular endothelial growth factor (VEGF) plays a central role in neoangiogenic processes.
  • For this reason, VEGF represents a target for the development of new therapeutic antiangiogenic molecules.
  • Clinical trials using anti-VEGF mAbs such as bevacizumab have validated the efficacy of this therapeutic approach but have also revealed adverse effects.
  • In mVEGF kinoid-immunized BALB/c mice challenged with syngeneic CT26 colorectal tumor cells, the number and size of lung metastases were significantly decreased.
  • In human (h)VEGF kinoid-immunized BALB/c mice, high levels of serum Abs to hVEGF were present, and purified IgG from these mice decreased by > or =50% the tumor growth of human A673 rhabdomyosarcoma cells and HT29 colon carcinoma xenografted in Swiss nude and NOD/SCID mice, respectively.
  • Tumor cell growth inhibition was similar to that observed in mice receiving therapeutic doses of bevacizumab.
  • These experiments suggest that a therapeutic vaccine containing VEGF kinoid may represent a strategy for safely combating VEGF-dependent neovascularization and metastases occurring in malignant tumors.
  • [MeSH-major] Cancer Vaccines / immunology. Cancer Vaccines / therapeutic use. Neoplasms / blood supply. Neoplasms / drug therapy. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / prevention & control. Vascular Endothelial Growth Factor A / immunology
  • [MeSH-minor] Animals. Antibodies / isolation & purification. Antibody Formation / immunology. Cell Line, Tumor. Colorectal Neoplasms / pathology. Female. HT29 Cells. Humans. Immune Sera. Immunization. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Metastasis. Paclitaxel / therapeutic use. Rhabdomyosarcoma / pathology. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5117-24 [11016638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19442-7 [17158801.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Jun;280(6):C1358-66 [11350730.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50 [11553767.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 19;93(24):1843-51 [11752008.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):33-42 [11926410.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Apr;14(2):123-37 [12651224.001]
  • [Cites] Drug Discov Today. 2004 Jan 15;9(2):72-81 [15012931.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):343-51 [15095298.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):3281-6 [15322190.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Bull Cancer. 1991;78(7):587-602 [1912670.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] J Biol Chem. 1997 Dec 12;272(50):31582-8 [9395496.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] J Cell Sci. 1999 Aug;112 ( Pt 16):2657-66 [10413674.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1089-99 [15809353.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35 [15961063.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):348-64 [16713103.001]
  • [CommentIn] Expert Rev Vaccines. 2007 Aug;6(4):491-6 [17669004.001]
  • (PMID = 17301234.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Cancer Vaccines; 0 / Immune Sera; 0 / Vascular Endothelial Growth Factor A; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1797624
  •  go-up   go-down


2. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


3. Ulusan S, Koç Z, Kayaselçuk F: Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment. Turk J Gastroenterol; 2008 Jun;19(2):129-32
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment.
  • Our objective was to show the unusual imaging characteristics of cystic liver metastases from a malignant gastrointestinal stromal tumor before and after treatment with imatinib mesylate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / ultrasonography. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Aged. Benzamides. Colon / pathology. Fatal Outcome. Humans. Imatinib Mesylate. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / ultrasonography. Intestine, Small / pathology. Liver / drug effects. Liver / pathology. Liver / ultrasonography. Male. Neoplasm Invasiveness. Stomach / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110671.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


Advertisement
4. Tseng SH, Liao CC, Lin SM, Chen Y, Shun CT: Dural metastasis in patients with malignant neoplasm and chronic subdural hematoma. Acta Neurol Scand; 2003 Jul;108(1):43-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural metastasis in patients with malignant neoplasm and chronic subdural hematoma.
  • OBJECTIVES: Dural metastasis associated with chronic subdural hematoma (CSH) is rare in patients with malignant neoplasm.
  • In this study, biopsy of the dura and cytological examination of the subdural hematoma was performed for patients with malignant neoplasm and chronic subdural hematoma to investigate the association of dural metastasis and CSH.
  • MATERIALS AND METHODS: Four patients with malignant neoplasm (one breast, one lung, and one colon cancers, and one lymphoma) were diagnosed with CSH.
  • CONCLUSION: The results suggest that dural metastasis should be considered in patients with malignant neoplasm and CSH.
  • Further, the prognosis for patients with malignant neoplasm and CSH may be poor because of systemic metastasis and the side-effects of chemotherapy.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / secondary. Breast Neoplasms / pathology. Colonic Neoplasms / pathology. Dura Mater / pathology. Dura Mater / surgery. Hematoma, Subdural, Chronic / complications. Hematoma, Subdural, Chronic / diagnosis. Lung Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Outcome Assessment (Health Care). Platelet Function Tests. Prothrombin Time. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12807392.001).
  • [ISSN] 0001-6314
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


5. Srivastava K, Singh S, Srivastava M, Srivastava AN: Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1183-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report.
  • Metastatic carcinoma in an abdominal wall incision from internal malignant neoplasm is an uncommon and often a preterminal event.
  • Most commonly metastatic skin incisional cancers have been reported with cancers of colon, kidney, and bladder.
  • We report a postoperative case of squamous cell carcinoma cervix FIGO stage IIA in a patient who after 3.5 years of completion of radical treatment (postoperative external and intravaginal radiation therapy) developed incisional skin metastasis followed by extensive subcutaneous metastasis in the vulval region.
  • She received salvage chemotherapy; however, she did not show any response and finally succumbed to the disease.
  • The intent of treatment remains palliation either by radiation/chemotherapy/surgery alone or in combinations.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Fatal Outcome. Female. Fluorouracil / administration & dosage. Gynecologic Surgical Procedures. Humans. Radiotherapy


6. Armbrust T, Sobotta M, Füzesi L, Grabbe E, Ramadori G: Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases. Eur J Gastroenterol Hepatol; 2007 Nov;19(11):988-94
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases.
  • BACKGROUND: Although modern chemotherapy of stage IV advanced colorectal cancer (CRC) has impressively improved overall survival, the response of the primary tumor has not been studied because surgical resection of the primary continues to be the standard procedure in stage IV CRC.
  • AIM: Long-term follow-up of the primary in patients with stage IV CRC under chemotherapy.
  • METHODS AND RESULTS: Here we report on the histological changes in the primary tumor in four patients suffering from stage IV CRC.
  • Systemic chemotherapy was started immediately after endoscopic tumor debulking in three cases.
  • In one case no endoscopic intervention was performed before chemotherapy.
  • Neither macroscopic nor histological evidence for malignant tumor growth was found at the former site of the primary after 6, 23, 26 or 48 months, respectively.
  • To date, three patients have died because of progression of liver metastases and one patient is still alive with no signs of tumor growth.
  • CONCLUSION: The four cases illustrate that today's chemotherapy may effectively induces suppression of the primary in CRC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / pathology. Aged. Colon / pathology. Colonic Polyps / drug therapy. Colonic Polyps / pathology. Colonic Polyps / surgery. Colonoscopy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049169.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Cambien B, Karimdjee BF, Richard-Fiardo P, Bziouech H, Barthel R, Millet MA, Martini V, Birnbaum D, Scoazec JY, Abello J, Al Saati T, Johnson MG, Sullivan TJ, Medina JC, Collins TL, Schmid-Alliana A, Schmid-Antomarchi H: Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer; 2009 Jun 2;100(11):1755-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism.
  • Recent research has indicated that CXCR3/chemokines interactions that orchestrate haematopoetic cell movement are implicated in the metastatic process of malignant tumours, including that of CRC cells to lymph nodes.
  • In vivo, systemic CXCR3 antagonism by preventive or curative treatments with AMG487 markedly inhibited the implantation and the growth of human and mouse CRC cells within lung without affecting that in the liver.
  • Altogether, our findings indicate that activation of CXCR3 receptors by its cognate ligands facilitates the implantation and the progression of CRC cells within lung tissues and that inhibition of this axis decreases pulmonary metastasis of CRC in two murine tumour models.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Cell Movement. Humans. Ligands. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Neoplasm Transplantation. Organ Specificity. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):627-32 [10627472.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):909-13 [12792744.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):409-18 [11310833.001]
  • [Cites] Arthritis Rheum. 2001 May;44(5):1022-32 [11352233.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):2812-24 [12960302.001]
  • [Cites] Immunol Lett. 2004 Mar 29;92(1-2):171-8 [15081542.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4010-7 [15173015.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] J Exp Med. 1993 Sep 1;178(3):1057-65 [8350046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13791-6 [8943014.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):963-9 [9064356.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):746-54 [9466968.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):318-29 [15647826.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):490-7 [15701832.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2428-35 [15536145.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1743-50 [15755995.001]
  • [Cites] Life Sci. 2006 Mar 13;78(16):1784-93 [16263140.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7701-7 [16885372.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):357-71 [17016763.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):139-47 [17218951.001]
  • [Cites] Gut. 2007 Mar;56(3):365-72 [16870716.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3396-405 [17409450.001]
  • [Cites] J Immunother. 2007 Jul-Aug;30(5):490-8 [17589289.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4679-88 [17297455.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1652-8 [17894551.001]
  • [Cites] ChemMedChem. 2008 Jun;3(6):861-72 [18442035.001]
  • [Cites] Cancer Gene Ther. 2002 May;9(5):432-42 [11961666.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):149-53 [11948506.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2606-10 [11980656.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):915-22 [12060384.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5546-54 [12421931.001]
  • [Cites] Hum Immunol. 2002 Dec;63(12):1164-71 [12480260.001]
  • [Cites] Hum Gene Ther. 2000 Jan 20;11(2):247-61 [10680839.001]
  • (PMID = 19436305.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, CXCR3
  • [Other-IDs] NLM/ PMC2695685
  •  go-up   go-down


8. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • We evaluated the rate of second malignancies in 1205 patients with osteosarcoma of the extremity treated at our Institution with different protocols of adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Of these, 2 developed a third cancer which were not considered in the series.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • Ten of these 26 patients are disease free at a median of 7.7 years (range 1 to 15 y) after the last treatment.
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Infant. Male. Neoplasms / drug therapy. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Maruyama M, Toukairin Y, Baba H, Kure N, Nagahama T, Ebuchi M: [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers]. Gan To Kagaku Ryoho; 2001 Oct;28(11):1505-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the pharmacokinetics of the intraperitoneal administration of CPT-11 for four patients with peritoneal metastasis (2 gastric cancer cases, 2 colon cancer cases).
  • Intraperitoneal therapy with CPT-11 was effective for the control of malignant ascites.
  • The high concentration of CPT-11 was achieved with intraperitoneal therapy and a small fraction of CPT-11 changed into SN-38 in the abdominal cavity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Camptothecin / analogs & derivatives. Camptothecin / pharmacokinetics. Colonic Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Injections, Intraperitoneal. Male. Middle Aged. Neoplasm Seeding

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707965.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Braumann C, Ordemann J, Wildbrett P, Jacobi CA: Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats. Clin Exp Metastasis; 2000;18(7):547-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent clinical and experimental studies investigated the problem and possible pathomechanisms of portsite metastases after laparoscopic resection of malignant tumours.
  • METHODS: After subcutaneous and intraperitoneal injection of 10(4) cells of colon adenocarcinoma (DHD/K12/TRb) the influences of either taurolidine or taurolidine/heparin on intraperitoneal and subcutaneous tumour growth were investigated in 105 rats undergoing laparoscopy with carbon dioxide.
  • CONCLUSIONS: The intraperitoneal therapy with taurolidine and the combination with heparin inhibits the intraperitoneal tumour growth and trocar recurrences.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heparin / therapeutic use. Laparoscopy / adverse effects. Peritoneal Neoplasms / drug therapy. Taurine / analogs & derivatives. Taurine / therapeutic use. Thiadiazines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Animals. Cell Division / drug effects. Drug Synergism. Injections, Intraperitoneal. Injections, Intravenous. Lymphopenia / etiology. Neoplasm Metastasis. Rats. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1998 Jul;133(7):762-6 [9688006.001]
  • [Cites] J Pharm Pharmacol. 1988 Jul;40(7):509-11 [2904994.001]
  • [Cites] Dis Colon Rectum. 1999 Jan;42(1):10-5 [10211514.001]
  • [Cites] World J Surg. 1998 Jan;22(1):55-60; discussion 60-1 [9465762.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):685-91 [11034247.001]
  • [Cites] Surg Endosc. 2000 Mar;14(3):239-42 [10741440.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S62-6 [8831549.001]
  • [Cites] Br J Clin Pharmacol. 1981 Nov;12(5):695-9 [7332737.001]
  • [Cites] Surgery. 1998 May;123(5):579-83 [9591012.001]
  • [Cites] Surgery. 1997 Jan;121(1):72-8 [9001554.001]
  • [Cites] Dig Surg. 1999;16(5):393-9 [10567800.001]
  • [Cites] J Endourol. 1993 Jun;7(3):237-41 [8358421.001]
  • [Cites] Br J Surg. 1997 Mar;84(3):358-61 [9117307.001]
  • [Cites] Langenbecks Arch Chir. 1997;382(4 Suppl 1):S26-30 [9333704.001]
  • [Cites] J Pediatr Surg. 1998 Mar;33(3):457-61 [9537557.001]
  • [Cites] Cytokine. 1991 Nov;3(6):568-75 [1790304.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2835-42 [1280480.001]
  • [Cites] Surgery. 1998 Apr;123(4):427-31 [9551069.001]
  • [Cites] Zentralbl Chir. 1997;122(12):1134-41 [9499540.001]
  • [Cites] Swiss Surg. 1997;3(6):266-73 [9427867.001]
  • [Cites] Surgery. 1993 Jul;114(1):87-91 [8356532.001]
  • [Cites] J Appl Bacteriol. 1987 Apr;62(4):315-20 [3298185.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):359-63 [9324156.001]
  • [Cites] Surgery. 1993 Mar;113(3):355-8 [7772085.001]
  • [Cites] Br J Surg. 1998 Jun;85(6):735-41 [9667697.001]
  • [Cites] Surg Endosc. 1997 Sep;11(9):902-6 [9294269.001]
  • [Cites] Surg Endosc. 1995 Mar;9(3):351-2 [7597614.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):151-5 [9234937.001]
  • [Cites] Surg Endosc. 2000 May;14(5):448-51 [10858469.001]
  • [Cites] Langenbecks Arch Chir. 1997;382(4 Suppl 1):S31-6 [9333705.001]
  • [Cites] Dis Colon Rectum. 1998 Jul;41(7):824-31 [9678366.001]
  • [Cites] Surgery. 1997 Jul;122(1):1-7 [9225907.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):419-22 [9559624.001]
  • [Cites] Virchows Arch. 1994;424(6):581-6 [8055151.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):400-4 [10201788.001]
  • [Cites] Surg Endosc. 1999 Oct;13(10):1021-5 [10526040.001]
  • (PMID = 11688959.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Thiadiazines; 1EQV5MLY3D / Taurine; 8OBZ1M4V3V / taurolidine; 9005-49-6 / Heparin
  •  go-up   go-down


11. Mischke A, Besier S, Walcher F, Waibel H, Brade V, Brandt C: [Spontaneous gas gangrene in a diabetic patient with Clostridium septicum]. Chirurg; 2005 Oct;76(10):983-6
Hazardous Substances Data Bank. CLINDAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] "Spontaner" Gasbrand mit Kompartmentsyndrom bei einem diabetischen Patienten.
  • In this case report, we present a patient with severe Clostridium septicum infection related to advanced colon cancer that had not previously been diagnosed.
  • It strongly suggests excluding malignant neoplasms, especially of the gastrointestinal tract, when severe Clostridium septicum infections occur.
  • Moreover, if patients with known colorectal or other malignancy develop septicaemia or spontaneous gas gangrene, clinicians should be aware of Clostridium septicum as one of the main causative agents, as early diagnosis and aggressive treatment are important to improve prognosis.
  • [MeSH-major] Adenocarcinoma / complications. Clostridium / isolation & purification. Colonic Neoplasms / complications. Diabetes Mellitus, Type 2 / complications. Gas Gangrene / etiology. Paraneoplastic Syndromes
  • [MeSH-minor] Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Clindamycin / administration & dosage. Clindamycin / therapeutic use. Colectomy. Colonoscopy. Debridement. Drug Therapy, Combination. Humans. Liver / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Penicillins / administration & dosage. Penicillins / therapeutic use. Radiography. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Emerg Med. 2003 May;24(4):401-5 [12745042.001]
  • [Cites] Pol Merkur Lekarski. 2004 Oct;17(100):403-6 [15690715.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):353-6 [10705386.001]
  • [Cites] ANZ J Surg. 2001 Nov;71(11):647-9 [11736823.001]
  • [Cites] Rev Esp Enferm Dig. 2002 Jun;94(6):361-6 [12432593.001]
  • [Cites] Rev Infect Dis. 1990 Mar-Apr;12(2):286-96 [2330482.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):30-7 [2642585.001]
  • (PMID = 16021394.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Penicillins; 3U02EL437C / Clindamycin
  •  go-up   go-down


12. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • Median RT dose was 45 Gy (range, 12.3 to 60 Gy) using 4 MV in 9, 1.25 MV in 8, 250 KV in 4, and 6 MV photons in 1 patient.
  • Fourteen had chemotherapy.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • Of 189 deaths occurring in 429 patients, only 3 (1.6%) were secondary to radiation-induced malignancy.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Lee SC, Wu CJ, Wu PY, Huang YL, Wu CW, Tao MH: Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene. J Biomed Sci; 2003 Jan-Feb;10(1):73-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene.
  • Intramuscular EP of pIL-12 resulted in complete regression or substantial inhibition of 38C13 B-cell lymphoma, whereas pIL-12 delivered by gene gun or intramuscular injection without EP showed little therapeutic effect.
  • Impressive antitumor activity by intramuscular EP was also demonstrated in animals with advanced malignant disease.
  • At day 14 after 38C13 tumor inoculation, all animals were found to carry large tumors and to have metastases; without treatment, most died within a week.
  • Moreover, animals that were previously cured of 38C13 tumors by in vivo EP treatment significantly suppressed tumor growth when challenged 60 days later.
  • In vivo EP of the IL-12 gene was also effective in suppressing subcutaneous and lung metastatic tumors of CT-26 colon adenocarcinoma and B16F1 melanoma cells.
  • Together, these results show that intramuscular electrotransfer of the IL-12 gene may represent a simple and effective strategy for cancer treatment.
  • [MeSH-major] Genetic Therapy / methods. Interleukin-12 / administration & dosage. Neoplasm Metastasis / prevention & control. Neoplasms, Experimental / therapy
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Electroporation. Female. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Mice. Mice, Inbred Strains. Muscle, Skeletal. Survival Rate. Time Factors. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 National Science Council, ROC and S. Karger AG, Basel
  • (PMID = 12566989.001).
  • [ISSN] 1021-7770
  • [Journal-full-title] Journal of biomedical science
  • [ISO-abbreviation] J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12
  •  go-up   go-down


14. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • Second neoplasm developed in 32 cases (4.8%).
  • Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia.
  • Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years.
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Ohana P, Schachter P, Ayesh B, Mizrahi A, Birman T, Schneider T, Matouk I, Ayesh S, Kuppen PJ, de Groot N, Czerniak A, Hochberg A: Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases. J Gene Med; 2005 Mar;7(3):366-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory sequences of H19 and IGF2 genes in DNA-based therapy of colorectal rat liver metastases.
  • BACKGROUND: Malignant tumors of the liver are among the most common causes of cancer-related death throughout the world.
  • Current therapeutic approaches fail to control the disease in most cases.
  • This study seeks to explore the potential utility of transcriptional regulatory sequences of the H19 and insulin growth factor 2 (IGF2) genes for directing tumor-selective expression of a toxin gene (A fragment of diphtheria toxin), delivered by non-viral vectors.
  • METHODS: The therapeutic potential of the toxin vectors driven by the H19 and the IGF2-P3 regulatory sequences was tested in a metastatic model of rat CC531 colon carcinoma in liver.
  • RESULTS: Intratumoral injection of these vectors into colon tumors implanted in the liver of rats induced an 88% and a 50% decrease respectively in the median tumor volume as compared with the control groups.
  • This therapeutic action was accompanied by increased necrosis of the tumor.
  • Importantly, no signs of toxicity were detected in healthy animals after their treatment by the toxin expression vectors.
  • CONCLUSIONS: DT-A was preferentially expressed in liver metastases after being transfected with H19 or IGF2-P3 promoter-driven DT-A expression plasmids, causing a very significant inhibition of tumor growth as a result of its cytotoxic effect.
  • Our findings strongly support the feasibility of our proposed therapeutic strategy, which may contribute to open new gene therapeutic options for human liver metastases.
  • [MeSH-major] Colorectal Neoplasms. DNA / metabolism. Genetic Therapy / methods. Liver Neoplasms / secondary. Proteins / genetics. RNA, Untranslated / genetics. Regulatory Sequences, Nucleic Acid
  • [MeSH-minor] Animals. Disease Models, Animal. Genes, Reporter. Humans. Insulin-Like Growth Factor II. Male. Neoplasm Metastasis. RNA, Long Noncoding. Rats. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 John Wiley & Sons, Ltd.
  • (PMID = 15521051.001).
  • [ISSN] 1099-498X
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / H19 long non-coding RNA; 0 / IGF2 protein, human; 0 / Proteins; 0 / RNA, Long Noncoding; 0 / RNA, Untranslated; 67763-97-7 / Insulin-Like Growth Factor II; 9007-49-2 / DNA
  •  go-up   go-down


16. Stelzner F, von Mallek D, Ruhlmann J, Biersack HJ: [PET-CT studies of metastasizing cancer of the colon and rectum. Variability of tumor aggressiveness as a micro-evolutionary process of cancer stem cells with predetermined prognosis]. Chirurg; 2009 Jul;80(7):645-51
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PET-CT studies of metastasizing cancer of the colon and rectum. Variability of tumor aggressiveness as a micro-evolutionary process of cancer stem cells with predetermined prognosis].
  • [Transliterated title] PET-CT-Untersuchungen zur Stammzellkarzinogenese im Kolorektalbereich. Malignitätsvariabilität als mikroevolutionärer Prozess mit festgelegter Prognose.
  • Formation of cancer stem cells which are both rare and variably therapy-resistant marks the beginning of a new disease without precursors.
  • Based on molecular changes, these cells are derived from normal cells and exhibit pre-programmed malignant behaviour.
  • Radical exstirpation of the primary tumor is able to cure the malignant process if the homing area is resected.
  • The primary tumor acts as the supplier of cancer stem cells for metastases which appear in different organs.
  • When chemotherapy is administered the distribution of metastases in different organs appears dependent of the response or non-response of cancer stem cells to this therapy.
  • Large numbers of colorectal carcinomas existed for the same time duration before death (15 years) independent of the malignancy grade.
  • The tumor metastasizes immediately after formation.
  • The primary tumor and the metastases appear variably quickly depending on the malignancy grade and are autonomic processes.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Colorectal Neoplasms / pathology. Image Processing, Computer-Assisted. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology. Neoplastic Stem Cells / pathology. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Biological Evolution. Cell Survival / drug effects. Cell Survival / genetics. Cell Survival / radiation effects. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Drug Resistance, Neoplasm / drug effects. Drug Resistance, Neoplasm / genetics. Drug Resistance, Neoplasm / radiation effects. Gene Transfer Techniques. Humans. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Organ Specificity. Probability Theory. Prognosis. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc R Soc Med. 1944 Feb;37(4):131-44 [19992767.001]
  • [Cites] Chirurg. 2006 Nov;77(11):1048-55 [17068665.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1394-9 [9102229.001]
  • [Cites] Chirurg. 2001 May;72 (5):537-46 [11383066.001]
  • [Cites] Chirurg. 2009 Apr;80(4):331-40 [18820881.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1177-83 [7909866.001]
  • [Cites] Surgery. 2007 Apr;141(4):415-9 [17383517.001]
  • [Cites] Chirurg. 2000 Oct;71(10):1230-4; discussion 1234-5 [11077584.001]
  • [Cites] Br J Surg. 1981 Dec;68(12):846-9 [7317765.001]
  • (PMID = 19562240.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Hishikawa Y, Kohno H, Ueda S, Kimoto T, Dhar DK, Kubota H, Tachibana M, Koji T, Nagasue N: Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology; 2001;61(2):162-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis.
  • Immunohistochemical staining for MT was performed on the specimens of adenocarcinoma of the colon and rectum and its liver metastases in 34 patients treated with curative surgery, respectively.
  • In the primary tumor, positive MT expression was significantly associated with a higher degree of lymph node involvement (mean +/- SD: 48.4 +/- 33.8 vs. 18.6 +/- 24.4% in MT-positive and MT-negative tumors, respectively; p = 0.0122).
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / chemistry. Liver Neoplasms / secondary. Metallothionein / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm. Female. Fluorouracil / administration & dosage. Humans. Life Tables. Male. Middle Aged. Mitomycin / administration & dosage. Multivariate Analysis. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11528256.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; 9038-94-2 / Metallothionein; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement